MedPath

Effectiveness of an Online Intervention Using a Feminist Approach on Gender Equality Promotion and Sexual Violence Prevention in China

Not Applicable
Completed
Conditions
Sexual Violence
Interventions
Behavioral: Sexual health intervention
Behavioral: Sexual Violence Prevention
Registration Number
NCT06353308
Lead Sponsor
The University of Hong Kong
Brief Summary

This paper presents the findings of a clustered randomized controlled trial (cRCT) that evaluated the effectiveness of an online feminist sexual health intervention among Chinese young adults, providing insights into the impacts of this innovative approach and contribute to the growing body of literature on feminist interventions for sexual health and equality promotion.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
422
Inclusion Criteria
  1. Young adults aged between 18-29 years old who possessed a mobile phone
  2. Had prior experience in using social media
  3. Were able to read and understand Chinese
Exclusion Criteria
  1. Those with a physical impediment (e.g., blindness) preventing them from accessing the mobile content

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
General Sexual Health interventionSexual health interventionParticipants will receive their general online sexual health education programming.
Feminist Sexual Health InterventionSexual Violence PreventionParticipants will receive online feminist sexual health program.
Primary Outcome Measures
NameTimeMethod
Rape myth acceptanceFrom enrollment to the end of treatment at one week and three months

Illinois Rape Myth Acceptance Scale -Short Form, which consists of 17 items (1=not at all agree, 7=very much agree) assessing respondents' belief in rape myths (e.g., "Rape happens when a man's sex drive gets out of control"). The scores range from 17 to 119, with lower scores indicating less subscription to rape myths.

Secondary Outcome Measures
NameTimeMethod
Sexual Attitudes ScaleFrom enrollment to the end of treatment at one week and three months

Sexual Attitudes Scale is a 22-item scale that includes: Permissiveness (six items); Responsibility (four items); Pleasure (four items); Instrumentality (four items); and Communion (four items). The factor items were rated on a five-point Likert-type scale ranging from 1 (strongly agree) to 5 (strongly disagree). After reverse-coding the negatively worded items, the item scores of each factor are summarized to obtain a total score for the factor. High scores indicated a high level of acceptance of the factor. The scores range from 22 to 110.

Sexual Desire InventoryFrom enrollment to the end of treatment at one week and three months

Sexual Desire Inventory is a self-reported scale developed to assess sexual desire. It has 14 items in two aspects: Dyadic Sexual Desire (DSD)and Solitary Sexual Desire (SSD). Items1,2,10 and14 are rated on 8-point scales with responses from 0 (Not at all or Always) to 7 (\> once a day or \< one day) and Items 3-9, 11-13 are rated on 9-point scales with responses from 0 (No desire, Not important at all, or Extremely low desire) to 8 (Strong desire, Extremely important, or High desire). High scores indicated a high level of sexual desire. The scores range from 0 to 108.

Sociocultural Attitudes toward AppearanceFrom enrollment to the end of treatment at one week and three months

Sociocultural Attitudes toward Appearance Questionnaire-3 consisted of eight items assessing the degree to which an individual accepts and internalizes societal standards of beauty. Examples include "I tend to compare my body to people in magazines and on TV" and "Women who appear in TV shows and movies project the type of appearance that I see as my goal." Each item is rated on a five-point Likert scale. The scores range from 8 to 40, with lower scores indicating less endorsement of sociocultural beauty standards.

Trial Locations

Locations (1)

The university of Hong Kong

🇭🇰

Hong Kong, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath